Soligenix Inc (SNGX) Stock Price, Quote & News

Company Profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 538 8200

Fax: 609 452 6467

Website: www.soligenix.com

Address:

29 Emmons Drive, Suite B-10, Princeton, United States

7CM Feb. 6 at 7:59 PM

$SNGX A potential repeat pattern between 30- 31st of July - lets see !

0 · Reply

JB20901 Feb. 6 at 7:43 PM

$SNGX filling the tank easy

0 · Reply

NetworkNewsWire Feb. 6 at 7:08 PM

NetworkNewsBreaks – $SNGX SGX945 Shows Promise with Immune-Modulating Approach https://nnw.fm/5qTuE

0 · Reply

jtabrizi Feb. 6 at 1:31 AM

$SNGX added heavy today

0 · Reply

BioMan_67 Feb. 5 at 10:58 PM

$SNGX probably bought as much as I can today. Fairly good bet imo. The FLASH1 data along with FDA guidance in designing FLASH2 suggests much more derisking than you’d normally have in a micro cap. Let’s see how it goes.

1 · Reply

Tonyboner Feb. 5 at 9:00 PM

$SNGX Dodged a bullet !

0 · Reply

GSlimzy Feb. 5 at 7:48 PM

$SNGX buying the dip. still see this going to $4 this year. haters gonna hate

1 · Reply

Bstyle13 Feb. 5 at 2:15 AM

$SNGX

0 · Reply

ieatbaguette Feb. 4 at 8:26 PM

$SNGX perfect bottom entry here

0 · Reply

Tonyboner Feb. 4 at 5:00 PM

$SNGX Darn not looking good, on watch but will not chase this one.

0 · Reply

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

Dec 17, 2025, 1:23 PM EST - 7 weeks ago

Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel

Dec 17, 2025, 7:30 AM EST - 7 weeks ago

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Dec 3, 2025, 8:30 AM EST - 2 months ago

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

Nov 19, 2025, 7:30 AM EST - 2 months ago

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Nov 7, 2025, 7:30 AM EST - 3 months ago

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Oct 14, 2025, 7:30 AM EDT - 4 months ago

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

Oct 7, 2025, 7:30 AM EDT - 4 months ago

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Sep 30, 2025, 7:30 AM EDT - 4 months ago

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Sep 29, 2025, 4:05 PM EDT - 4 months ago

Soligenix Announces Closing of $7.5 Million Public Offering

Sep 26, 2025, 6:33 AM EDT - 4 months ago

Soligenix Announces Pricing of $7.5 Million Public Offering

Sep 23, 2025, 7:30 AM EDT - 4 months ago

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

Sep 4, 2025, 7:30 AM EDT - 5 months ago

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

Sep 2, 2025, 7:30 AM EDT - 5 months ago

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 18, 2025, 1:03 PM EDT - 6 months ago

Why Is Soligenix Stock Soaring On Monday?

Aug 18, 2025, 7:30 AM EDT - 6 months ago

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

Aug 14, 2025, 7:30 AM EDT - 6 months ago

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

Aug 8, 2025, 8:30 AM EDT - 6 months ago

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

Jul 31, 2025, 7:30 AM EDT - 6 months ago

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

Jul 8, 2025, 7:30 AM EDT - 7 months ago

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Jul 1, 2025, 7:30 AM EDT - 7 months ago

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Jun 6, 2025, 9:37 AM EDT - 8 months ago

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

May 9, 2025, 7:30 AM EDT - 9 months ago

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

Apr 14, 2025, 7:30 AM EDT - 10 months ago

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

Mar 25, 2025, 8:30 AM EDT - 11 months ago

IBN Initiates Coverage of Soligenix Inc.

Mar 25, 2025, 7:30 AM EDT - 11 months ago

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Mar 21, 2025, 7:30 AM EDT - 11 months ago

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

Mar 6, 2025, 7:30 AM EST - 1 year ago

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Feb 4, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at BIO CEO & Investor Conference

Jan 16, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at Upcoming Investor Conferences

Jan 14, 2025, 7:30 AM EST - 1 year ago

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Dec 16, 2024, 7:30 AM EST - 1 year ago

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Dec 2, 2024, 7:30 AM EST - 1 year ago

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Nov 19, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Nov 15, 2024, 7:30 AM EST - 1 year ago

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Nov 14, 2024, 7:15 AM EST - 1 year ago

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Nov 8, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Oct 22, 2024, 7:30 AM EDT - 1 year ago

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Oct 16, 2024, 7:30 AM EDT - 1 year ago

Soligenix Invited to Present at Upcoming Investor Conferences

Oct 7, 2024, 7:30 AM EDT - 1 year ago

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

Oct 3, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Partnership with Sterling Pharma Solutions

Sep 20, 2024, 9:00 AM EDT - 1 year ago

Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Sep 16, 2024, 7:30 AM EDT - 1 year ago

Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Soligenix Receives European Patent for Improved Production of Synthetic Hypericin

Aug 16, 2024, 9:00 AM EDT - 1 year ago

Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

AREC

Aug 9, 2024, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results

Jul 15, 2024, 10:16 AM EDT - 1 year ago

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

Jul 9, 2024, 12:46 PM EDT - 1 year ago

Soligenix stock rallies 400% on positive HyBryte trial results

Jul 9, 2024, 12:11 PM EDT - 1 year ago

Crude Oil Down 1%; Soligenix Shares Surge

Jul 9, 2024, 11:38 AM EDT - 1 year ago

Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why

7CM Feb. 6 at 7:59 PM

$SNGX A potential repeat pattern between 30- 31st of July - lets see !

0 · Reply

JB20901 Feb. 6 at 7:43 PM

$SNGX filling the tank easy

0 · Reply

NetworkNewsWire Feb. 6 at 7:08 PM

NetworkNewsBreaks – $SNGX SGX945 Shows Promise with Immune-Modulating Approach https://nnw.fm/5qTuE

0 · Reply

jtabrizi Feb. 6 at 1:31 AM

$SNGX added heavy today

0 · Reply

BioMan_67 Feb. 5 at 10:58 PM

1 · Reply

Tonyboner Feb. 5 at 9:00 PM

$SNGX Dodged a bullet !

0 · Reply

GSlimzy Feb. 5 at 7:48 PM

$SNGX buying the dip. still see this going to $4 this year. haters gonna hate

1 · Reply

Bstyle13 Feb. 5 at 2:15 AM

$SNGX

0 · Reply

ieatbaguette Feb. 4 at 8:26 PM

$SNGX perfect bottom entry here

0 · Reply

Tonyboner Feb. 4 at 5:00 PM

$SNGX Darn not looking good, on watch but will not chase this one.

0 · Reply

GreedyGopher Feb. 4 at 4:54 PM

$SNGX If you bought 1000 shares of SNGX in 2022... you would now have 4 shares due to their reverse splits then dilution.....and about to be in sub$1 yet again. Let that sink in ..............never brought anything to market and never will...... cutting edge biomedical solutions? Google their corporate headquarters.... in a single story office suite next to a daycare in Jersey......look for yourself

1 · Reply

GreedyGopher Feb. 4 at 4:28 PM

$SNGX Time for yet ANOTHER reverse split followed by dilution. This is how SNGX turns your position into zero.......Never brought anything to market and never will.......thank you.. come again

0 · Reply

uptrend2025 Feb. 3 at 7:18 PM

$SNGX This one could pop soon

1 · Reply

Bhaddar1 Feb. 3 at 4:49 PM

$SNGX buy it xx

0 · Reply

NetworkNewsWire Feb. 2 at 6:11 PM

$SNGX Builds Momentum in Fight Against Rare, Chronic Cancer https://ibn.fm/AExFL

0 · Reply

JB20901 Jan. 30 at 10:19 PM

$SNGX perfect

0 · Reply

Bhaddar1 Jan. 30 at 9:33 PM

$APRE These dips are gift 🎁 And $SNGX $CRIS Buy and Hold $7

1 · Reply

NetworkNewsWire Jan. 30 at 7:10 PM

$SNGX Positioning for Impact in Growing Rare-Disease Landscape https://ibn.fm/Cen9T

0 · Reply

7CM Jan. 30 at 2:19 PM

$SNGX

0 · Reply

NetworkNewsWire Jan. 29 at 6:03 PM

BioMedNewsBreaks — $SNGX Targets Critical Gaps in CTCL Treatment with HyBryte(TM) https://ibn.fm/pnI2N

0 · Reply

jtabrizi Jan. 28 at 7:31 PM

$SNGX added here

0 · Reply

rrch Jan. 28 at 4:41 PM

$SNGX want to see a European partner

0 · Reply

Market Cap	11.40M
Revenue (ttm)	120,000.00
Net Income (ttm)	-8.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,891.67%
Debt to Equity Ratio	0.00

Volume	149,600
Avg Vol	305,686
Day's Range	N/A - N/A
Shares Out	10.09M
Stochastic %K	28%
Beta	2.01
Analysts	Strong Buy
Price Target	$17.50